---
title: "Nektar Therapeutics Reports Q3 2025 Financial Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264784390.md"
description: "Nektar Therapeutics (NKTR) reported its Q3 2025 financial results, revealing a revenue drop to $11.8 million from $24.1 million in Q3 2024, mainly due to the sale of its Huntsville manufacturing facility. The net loss improved slightly to $35.5 million from $37.1 million year-over-year. Operating costs decreased to $43.5 million, attributed to reduced R&D expenses. The company raised capital through stock offerings and received FDA Fast Track designation for its lead product, rezpegaldesleukin, targeting severe alopecia areata. Nektar aims to advance its pipeline and sustain operations into Q2 2027."
datetime: "2025-11-07T04:55:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264784390.md)
  - [en](https://longbridge.com/en/news/264784390.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264784390.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264784390.md) | [繁體中文](https://longbridge.com/zh-HK/news/264784390.md)


# Nektar Therapeutics Reports Q3 2025 Financial Results

Nektar Therapeutics ( (NKTR) ) has released its Q3 earnings. Here is a breakdown of the information Nektar Therapeutics presented to its investors.

### Meet Your ETF AI Analyst

-   Discover how TipRanks' _ETF_ AI Analyst can help you make smarter investment decisions
-   Explore ETFs TipRanks' users love and see what insights the **_ETF_ AI Analyst** reveals about the ones you follow.

Nektar Therapeutics is a clinical-stage biotechnology company based in San Francisco, focusing on developing treatments for autoimmune and chronic inflammatory diseases. Its lead product candidate, rezpegaldesleukin, is a novel regulatory T cell stimulator being evaluated in multiple clinical trials.

In its third-quarter 2025 earnings report, Nektar Therapeutics highlighted a decrease in revenue to $11.8 million compared to $24.1 million in the same quarter of 2024, primarily due to the sale of its Huntsville manufacturing facility. The company also reported a net loss of $35.5 million, slightly improved from the previous year’s third-quarter loss of $37.1 million.

Key financial metrics showed a reduction in operating costs and expenses, which totaled $43.5 million for the third quarter of 2025, down from $58.5 million in the previous year. This decrease was attributed to reduced research and development expenses and the elimination of costs following the sale of the manufacturing facility. Additionally, Nektar raised significant capital through stock offerings, bolstering its cash reserves.

Strategically, Nektar made notable progress with rezpegaldesleukin, receiving FDA Fast Track designation for treating severe alopecia areata and presenting promising data at major scientific meetings. These developments position the company to potentially capture a unique market niche in treating atopic dermatitis and related conditions.

Looking ahead, Nektar Therapeutics remains focused on advancing its pipeline, with expectations to sustain operations into the second quarter of 2027. The company is optimistic about upcoming data releases and the continued development of its innovative therapies.

### Related Stocks

- [Nektar Therapeutics (NKTR.US)](https://longbridge.com/en/quote/NKTR.US.md)

## Related News & Research

- [Insig AI Plans Growth Drive and Eyes Nasdaq Dual Listing](https://longbridge.com/en/news/281311983.md)
- [Meet 'Dobby': The AI agent that could kill the app economy](https://longbridge.com/en/news/281354277.md)
- [SharonAI Secures Major Long-Term AI Cloud Services Deal](https://longbridge.com/en/news/281363534.md)
- [Realbotix to Deliver 19 AI Humanoid Robots as It Scales Production](https://longbridge.com/en/news/281387250.md)
- [Legal AI startup Legora hits $100 million in annual recurring revenue](https://longbridge.com/en/news/281411319.md)